Patricia Inácio, PhD, science writer —

An investigational therapy, ATH434 was able to reverse some gastrointestinal problems in a mouse model of Parkinson’s disease, according to its developer Alterity Therapeutics. “Practicing clinicians are well aware of the substantial impact that these symptoms have on the quality of life of individuals with Parkinson’s disease,” David Stamler,…

The U.S. Food and Drug Administration has approved Insightec’s incision-free brain “surgery” technology — Exablate Neuro — for the treatment of motor symptoms in Parkinson’s disease patients. According to the company, the device is indicated to use in patients with moderate-to-severe motor complications, such as tremors, stiffness and uncontrolled, involuntary movement…

Scientists at the Duke University School of Medicine have received two grants totaling $18 million to investigate how different cells in the brain and in the gut may foster the onset and progression of Parkinson’s disease. The grants from the Aligning Science Across Parkinson’s (ASAP) initiative will fund two…

A clinical study is assessing whether a specific type of rehabilitation therapy — called neurologic music therapy — may help people with Parkinson’s disease recover fine motor skills, such as those required for writing, self-care, and fine object manipulation. The trial (NCT03049033) is underway at the University of…

A new Phase 2 clinical trial will test the psychedelic painkiller ketamine as a treatment for levodopa-induced dyskinesia in people with Parkinson’s disease. The trial, called KET-LID (NCT04912115), is expected to start enrolling participants this month. The first results are expected by the end of the year. Launched by …

A Phase 1 trial of AP-472, Appello Pharmaceutical‘s lead investigational therapy to ease levodopa-induced dyskinesia in Parkinson’s disease, has started dosing healthy adults. The study will randomly assign young, middle-aged, and elderly adults to escalating doses of AP-472 or a placebo. It aims to evaluate the therapy’s safety, tolerability, and…

A medical student at the University of Queensland has won a U.S. Parkinson’s Foundation fellowship to investigate new ways to halt chronic brain inflammation and the death of dopamine-producing neurons in Parkinson’s disease. Zhen-Yi Andy Ou was awarded one of 11 fellowships for the project “Targeting novel…

Intrance Medical Systems has raised $8 million to support a planned U.S. clinical trial of its fixed-dose combination of levodopa, carbidopa, and entacapone in advanced Parkinson’s disease patients. The combo therapy, originally developed by Lobsor Pharmaceuticals and sold under the name Lecigon in Nordic countries —  Denmark, Finland, Iceland, Norway and Sweden, and their…

Top-line results are expected to be released by the end of this year for Pharma Two B’s multinational trial investigating the safety and efficacy of P2B001 for treating early stage Parkinson’s disease. Pharma Two B announced that its researchers have finished treating patients in the Phase 3 trial, which…

Several new clinical trial data analyses support the benefits and superiority of Gocovri (amantadine) over other therapies in lessening off episodes — periods when levodopa treatments stop working and motor symptoms return — and involuntary movements called dyskinesia in people with Parkinson’s disease. These analyses compared Gocovri, marketed by…